In a diverse cohort of virologically suppressed women with HIV, long-acting cabotegravir and rilpivirine (CAB+RPV LA) maintained high rates of viral suppression with low virologic failure over a median...
Researchers evaluated the safety and efficacy of dolutegravir plus lamivudine in treatment-naive individuals with HIV without baseline resistance testing.
The CDC reported more than 200,000 cases of syphilis in 2022, a 17% increase compared with the previous year. In response, the CDC provided new recommendations for testing syphilis in the laboratory.
Pre-exposure prophylaxis (PrEP) adherence continues to be one of the main challenges for the elimination of HIV transmission. Researchers tested the use of an automated directly observed therapy...
In a recent study, researchers examined the effectiveness of text messaging to support the use of pre-exposure prophylaxis use in certain patient populations who are at high-risk of HIV infection.
Researchers aimed to determine the risk profile of individuals without HIV who were seeking vaccination against mpox and if these patients would benefit from HIV pre-exposure prophylaxis use.
To better understand the relationship between cardiovascular disease and liver disease in individuals with HIV, researchers examined both traditional risk factors and HIV-specific risk factors of the...
